Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SAMRAT PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SAMRAT PHARMA   MYLAN
EQUITY SHARE DATA
    SAMRAT PHARMA
Mar-23
MYLAN
Dec-18
SAMRAT PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,2503,967-   
Low Rs3322,184-   
Sales per share (Unadj.) Rs1,005.31,825.4-  
Earnings per share (Unadj.) Rs53.849.6-  
Cash flow per share (Unadj.) Rs55.9391.3-  
Dividends per share (Unadj.) Rs1.000-  
Avg Dividend yield %0.10-  
Book value per share (Unadj.) Rs204.31,974.7-  
Shares outstanding (eoy) m3.09514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.81.7 46.7%   
Avg P/E ratio x14.762.0 23.7%  
P/CF ratio (eoy) x14.17.9 180.1%  
Price / Book Value ratio x3.91.6 248.5%  
Dividend payout %1.90-   
Avg Mkt Cap Rs m2,4441,582,214 0.2%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m110-   
Avg. sales/employee Rs Th026,833.1-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0728.6-  
INCOME DATA
Net Sales Rs m3,106939,158 0.3%  
Other income Rs m50-   
Total revenues Rs m3,111939,158 0.3%   
Gross profit Rs m239243,019 0.1%  
Depreciation Rs m6175,847 0.0%   
Interest Rs m1245,170 0.0%   
Profit before tax Rs m22522,002 1.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m59-3,500 -1.7%   
Profit after tax Rs m16625,502 0.7%  
Gross profit margin %7.725.9 29.8%  
Effective tax rate %26.2-15.9 -164.6%   
Net profit margin %5.42.7 197.2%  
BALANCE SHEET DATA
Current assets Rs m986524,425 0.2%   
Current liabilities Rs m528382,364 0.1%   
Net working cap to sales %14.815.1 97.6%  
Current ratio x1.91.4 136.3%  
Inventory Days Days884 9.6%  
Debtors Days Days60293 645.2%  
Net fixed assets Rs m175182,181 0.1%   
Share capital Rs m31500 6.2%   
"Free" reserves Rs m6010-   
Net worth Rs m6311,015,998 0.1%   
Long term debt Rs m01,096,588 0.0%   
Total assets Rs m1,1622,725,301 0.0%  
Interest coverage x19.31.5 1,297.0%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x2.70.3 776.1%   
Return on assets %15.42.6 593.0%  
Return on equity %26.32.5 1,049.3%  
Return on capital %37.63.2 1,183.5%  
Exports to sales %4.10-   
Imports to sales %83.30-   
Net fx Rs m-2,4600-   
CASH FLOW
From Operations Rs m-94195,157 -0.0%  
From Investments Rs m-30-100,875 0.0%  
From Financial Activity Rs m96-90,916 -0.1%  
Net Cashflow Rs m-281,617 -1.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.34 Rs / USD

Compare SAMRAT PHARMA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare SAMRAT PHARMA With: STRIDES PHARMA SCIENCE  KOPRAN.  EVEREST ORGANICS  NATURAL CAPS  SMS LIFESCIENCES INDIA  



Today's Market

Sensex Today Trades Flat | Nifty at 22,600 | Tech Mahindra Jumps 12% Sensex Today Trades Flat | Nifty at 22,600 | Tech Mahindra Jumps 12%(10:30 am)

Asian shares rose cautiously on Friday as markets sobered up to the idea that U.S. rate cuts were most likely some time away.